PND38 Cost Minimization Analysis of Fingolimod Versus Natalizumab in the Second-Line Treatment of Remittent-Recurrent Multiple Sclerosis

Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1962
https://www.valueinhealthjournal.com/article/S1098-3015(12)03675-3/fulltext
Title : PND38 Cost Minimization Analysis of Fingolimod Versus Natalizumab in the Second-Line Treatment of Remittent-Recurrent Multiple Sclerosis
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03675-3&doi=10.1016/j.jval.2012.08.1962
First page : A552
Section Title : Neurological Disorders
Open access? : No
Section Order : 1450
Categories :
Tags :
Regions :
ViH Article Tags :